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INTRODUCTION 
Systemic lupus Erythematosus (SLE) is an autoimmune 
inflammatory disorder. It is characterized by multi system involvement 
and is heterogenous in its presentation. It is associated with numerous 
antibodies and immune complex formation. It predominantly affects 
females in their peak reproductive period (F:M=9:1) and in other age 
groups (3:1). Multiple factors like environmental, genetic and hormones 
have been implicated in the pathogenesis of this disorder. Under the 
wider spectrum of molecular biology, using newer immunological 
techniques, many antibodies along with the epitopes have been 
discovered which help in further understanding the disease. This 
disease, which is one of the major differentiated connective tissue 
disorders, affects all the organs as the disease progresses. The disease 
activity judged by using various measures is unable to accurately 
anticipate the morbidity and mortality because of its heterogeneity. It 
has protean manifestations and encompasses a wide age range from 
neonates to the elderly. 
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AIM AND OBJECTIVES 
To study the clinical profile of systemic lupus erythematosus in 
children and adults as it is seen in this part of the country. 
To study the association of Colour Duplex Doppler of the 
carotids along with associated traditional risk factors like age, disease 
duration, smoking, family history of athersclerotic disease and 
laboratory variables along with SLEDAI, steroid usage and lipid profile 
in SLE patients.  
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ABBREVIATION 
SLE  : Systemic Lupus Erythematosus 
CRP  : C Reactive Protein 
RF  : Rheumatoid factor.  
ACL  : Anti cardiolipin Antibody 
ANA  : Anti Nuclear Antibody 
ssDNA  :  Single Stranded Deoxyribonucleic Acid 
ds DNA : Double Stranded Deoxy Ribo Nucleic Acid 
LAC  : Lupus Anti Coagulant 
IIF  : Indirect Immuno Fluorescence 
Sm  : Smith Antibody 
U1RNP : Uridyl 1 Ribonucleoprotein 
SLEDAI : SLE Disease Activity Index 
CAD   :  Coronary arterial disease 
TCL   :  Total cholesterol 
HDL   :  High density lipoprotein cholesterol 
LDL   :  Low density lipoprotein cholesterol 
TGL   :  Triglycerides 
S I   :  South India - Chandrasekharan A.N. et al study 
NK   :  Northern Kerala - Binoy J. Paul et al study 
NI   :  North India - Malaviya A.N. et al study 
IMT   : Intimomedial thickness 
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REVIEW OF LITERATURE 
SLE is a connective tissue disease wherein tissues and cells are 
damaged by auto antibodies and immune complexes, and infections are 
the major cause of morbidity and mortality.  
History 
The first historical event of describing Lupus Erythematosus was 
by T. Biett (1833). In 1845, Van Hebra described butterfly rash, and in 
1872 Kaposi described its systemic involvement. Hargrave’s et al1 in 
1948 discovered the LE cell. Lee et al2 showed that the antibodies are of 
Immunoglobulin in nature and it is the LE factor, which forms the LE 
body. Knowledge in understanding the disease was initiated by 
discovery of the Immunofluorscence technique in 1957 by Hallborough 
using human cells. In 1961 Beck et al. used rodent tissue for  
immunofluoroscence and later in 1982, Tan used HEp 2 cells which 
improved the better understanding of the antibodies pattern. Other 
laboratory landmarks in SLE are, BFP (biologically false positive) 
VDRL reaction – Reinhart (1909), Wireloop glomeruli – Baehr, (1935), 
LAC – Hartmann, (1952) and ANA – Miescher, Fauconnet, (1954) Tan 
and Kunkel3 described anti Sm anti body in 1966.  
Cazenave described Lupus Erythemateaux in 1851 in France. 
Kaposis first showed visceral involvement in SLE in 1872. TAN in 1982 
proposed the revised American College of Rheumatology criteria for 
classification of SLE.  
Epidemiology 
SLE prevalence varies in different geographical areas. Johnson et 
al. reported in his study that the prevalence rates 36.2, 90.6 and 206 
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per100, 000 among women of Caucasian, Asian and Afro Caribbean 
origin respectively4,5.  
In certain countries like San Fransico, Sweden and Nottingham 
the prevalence is 51, 36.3 and 24.6 per one lakh and the incident rate 
which denotes new cases every year is 7.6, 4.5 and 4 per one lakh 
respectively. The incidence in children is 0.6 – 0.8 per one lakh6,10. The 
F:M sex ratio in children is 1.4 – 5.8: 1 and in adults 8:1 to 13:1.  
The frequency of presentation of SLE in different age groups is as 
follows 1) between 16–55 it is 65%, 2) below 16 it is 20% and 3) above 
55 it is 15%.  
SLE is 3 times more common in Blacks who have more Sm and 
RNP antibodies, discoid skin lesions, cellular casts and serositis7.  
Immunopathogenesis 
Genetics 
Support for genetic factors comes from the following facts like 
high prevalence among monozygotic twins (24%) and the highest 
reported is 58%. 5-12% of the relatives of SLE patients develop the 
disease6,8.  
Genetic  
a.  Complement C1, C4 def.  > 75% prevalence, 
severe disease 
  C2 def. 35% prevalence 
  C4 50-80% patients 
partially deficient 
b.  MHC 
Association 
HLA : A1, B8, DR3 English patients 
  DR2, DQw4 (DQw6), DQ2 Susceptibility to 
nephritis 
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  DRw8 Early onset SLE (<20 
yrs)
  DQw6, 7, 8 Lupus anticoagulant
  DQB1 0201, 0302 Antids DNA 
  DQw6 Anti Sm 
  DR-7 More severe disease
  DR-3 AntiRo/antiLa, 
neonatal lupus 
c.  Non HLA genes T cell receptor genes (assoc; with anti-Ro)
  Ig heavy chain (Gm) Km light chain genes 
  Homozygons deletion of 
Ig VH gene
 
d.  Newer 
Polymorphism 
TNF 308 A, FC ϒIIA, FC 
ϒIIIA and FC ϒIIIB, 
MBL, IL 4, IL 10, PARP, 
CR 1. Fas, Fas ligand
 
 
Environmental factors 
Definite- Ultra Violet B-rays in the range 300-360 nanometers 
penetrate the deeper layers of the skin and cause necrosis of the basal 
layer. This leads to antigen flip-flop towards the outside of the 
membrane through Apoptotic bleb and thus when exposed to the 
antibodies form antigen antibody complexes. Circulating ANA’s will 
further cause inflammation even after the initiating stimuli is 
withdrawn8,12.  
Hormonal-Sex hormones F:M ratio is 9:1 between menarche and 
menopause & 3:2 in the young & old. 
Dietary factors like alfalfa (L-canavanine), high calorie diet, high 
intake of saturated fats and infections–retroviruses, bacterial 
lipopolysaccharide, EBV (James, et al, 1997) have been implicated. 
Drugs–hydralazine, procainamide, INH, hydantoin, Alpha 
methyldopa, chlorpromazine, D-penicillamine and α-interferon.  
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Abnormal immune response and pathogenesis 
The immunopathogenesis is multi factorial.  SLE is a CD4 T cell 
dependent disease. The foreign antigens are presented to the T cells 
through MHC class II molecules. Clones of auto reactive B cells have 
been seen in active SLE. They depend on IL 6 cytokine for their 
proliferation. They are dependent on the T helper cells (CD 4). These T 
cells also show hyperactivity due to stimulation of antigen presented by 
the various antigen-presenting cells like dendritic cell. They belong to 
the groups like CD 5 marker B1 cell, CD -4-8-(double negative) and CD 
4+8- cells which escape the central and peripheral tolerance. Due to this 
dysregulation of immune system occurs. This is modified by infection 
and genetic abnormalities which eventually leads on to generation of 
various anti bodies by epitope spreading6,12.  
Abberations in the recombination of VDJ region genes of 
immunoglobulin heavy chain and VJ of light chain generate antibodies.  
 Pathogenic antibodies mutations arise from the invariable region 
often in frame work area. The anti ds DNA through its cationic charge, 
increase acidity, charge to charge hydrogen bonding and interaction with 
the molecules in the antigen produces increased avidity. 
 Cytokines involved in SLE are interleukin (IL) –4, IL 10, along 
with defective IL 2 production in the regulatory cells CD4+25+, which 
promotes CD4 T cells proliferation. During inflammation of tissues 
there is an increase of Th1 cytokines like interferon ϒ, TNF α by T cell 
and IL 1 is produced by macrophages spontaneously. This persistent 
Tcell activation prevents anergy induction.  
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Diagnostic criteria 
The presence of 4 or more of Revised American College of 
Rheumatology Criteria (1982) is essential to make a diagnosis of SLE 
with 98% specificity & 97% sensitivity1. Appendix1.  
Auto antibodies in SLE 
 They primarily target nucleic constituents including DNA, RNA 
proteins & RNP complexes. They also bind to cell surface and cellular 
antigens11,12. 
Intracellular Ag-Antibodies to ds DNA (80%), ss DNA (90%), 
Ribosomal (10-15%), Histone (42-50%), Ro (SS-A), (40-50%), La/SS-B 
(15%), Sm (30%), U1RNP (30-50%), 28 S RNA, RNA polymerase II 
(12%), Ku (20-40%) and Proteasome (58%). 
Membrane level-Antibodies against Lymphocyte (>50%), RBC 
(10-50%), Platelet (10%), APLS-ACL (30%) and APLS LAC (50%). 
These antibodies are of diagnostic, prognostic significance as well 
as produce immunopathological changes characteristics of disease.  
Antibodies to nucleosome is the recent finding in lupus nephritis. 
Initiated by these antibodies, and extended by epitope spreading, antids 
DNA and histones are generated by stimulated autoreactive B cells. 
J.A.Simon et al in 2003 described the potential utility of 
nucleosome antibodies and concluded that it can be used as diagnostic 
tool and disease activity marker66.  
ANA is detected by ELISA which is sensitive 98%-100% but 
immunofluorescent assay by HEp2 cells at dilution of 1:160 is more 
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specific and sensitive. The sensitivity using rodent cell is about 70% 
only. Anti ds DNA is detected by ELISA, RIA (Farr–gold standard) are 
more sensitive than Crithidia lucillae assay, which is specific. 
Antibodies to extractable nuclear antigens like Sm, U1RNP, Ro, La, 
Jo1and Scl-70 are identified by immuno precipitation and ELISA. 
Presence of antibodies to Jo1 and Scl-70 in SLE may be seen in overlap 
and increases the severity of the disease.  
CLINICAL FEATURES  
1. Constitutional: Fever is seen in childhood onset SLE in 70%10. 
Fatiguability is seen during flare. Lupus crisis denotes active lupus. 
Chills, leukocytosis and increased CRP favour infection.  
2.  Mucocutaneous: Skin and mucous membrane is involved in 80% 
of cases. SLE skin lesions are described as SLE specific and nonspecific 
under Gilliam’s classification. 
LE specific lesions Acute: (30-50), Malar rash, Generalised 
erythema and Bullous LE/TEN like lesion 
Subacute cutaneous lupus (SCLE) (10-15), Annular polycyclic, 
Papulosquamous. 
Chronic lupus (CLE) (10-15), Localised discoid, Generalised 
discoid and Lupus profundus. 
LE Nonspecific lesions: Panniculitis, Urticaria, Vasculitis, Livedo 
reticularis, Nonscarring alopecia, Hyperpigmentation, Pruritus, Leg 
ulcer, S/C nodules. 
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Pathogenesis  
Anti Ro(SSA) & La(SSB) antibodies correlate with the 
development of SCLE skin lesions. In the skin IL-1 and TNF-α are 
increasingly produced along with heat shock proteins.  
Lupus band test is positive in non lesional unexposed and lesional 
skin in SLE whereas only lesional skin is positive in DLE (described by 
Burnham in 1907). In 10- 20% of SLE patients have discoid lesions. 2-
10% of DLE evolve into SLE. ANA is positive in 22-62% of DLE and 
along with anti ss DNA in 90% denotes more severe disease. SCLE 
lesions are nonfixed, nonscarring, with remissions and exacerbations, 
occurs in sun-exposed areas of the extensor aspect of forearms, upper 
neck and chest and is associated with HLA DR3 and is anti Ro(SSA) 
antibody positive.  
Histopathology of ACLE shows liquefactive and vacuolar 
degeneration of basal cell layer, pigmentary incontinence, 
hyperkeratosis, edema of the upper dermis and perivascular infilteration 
of monocytes, as seen in the photograph Plate 1.  
SCLE lesions shows variable degrees of hyperkeratosis, focal 
basal cell degeneration, dermal edema and rarely vesicular changes can 
occur particularly at the active border of the annular SCLE. 
DLE lesions show follicular plugging, atrophy, scarring, erythema 
and telangiectasia, which commonly occurs in the scalp and trunk. 
SCLE is due to antibody-mediated cytotoxicity and DLE is due to T-cell 
mediated cytotoxicity. Plate 2. 
In children malar rash 55%, alopecia 20%, oral ulcer 50% and 
photosensitivity seen in 50%6,10. Non specific lesion palmar erythema, 
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atrophic blanche, urticarial lesion, livedoreticularis, chilblain, 
epidermolysis bullosa, dermatitis herpetiformis, pemphigoid and 
epidermolysis bullosa acquisita have been reported in adults14,15,16. 
3.  Musculo skeletal manifestation is seen in about 95% of 
patients8,9. At the onset, arthritis is seen about 45-65% in various 
studies. During the disease course, arthritis is seen in 71% deformities 
in 30% and nodules in 5%. Jaccoud’s involving small joints of the hands 
is seen in 15-20%. In children arthritis is seen in 75% and is non 
erosive. Spontaneous tendon rupture and septic arthritis have been 
reported. Avascular necrosis is seen commonly in the hips because of 
APLS, steroids usage, fat embolism and vasculitis of small vessels. 
Myositis is seen in 20%, it may be due to disease, drugs commonly 
steroids and chloroquine and overlap syndromes. Muscles involved are 
the proximal group usually but rarely the distal group, as seen in 
dermatomyositis SLE overlap 3-5%. Fibromyalgia is seen in 2-5%, 
which also contributes to the fatiguability. Vacuolar and nemaline rod 
myopathy are seen rarely.  
Drug induced myopathy may be differentiated by predominantly 
affection of type 2 fibres (electron microscopy) but muscle enzymes are 
normal.  
4. Gastrointestinal manifestations in SLE include, recurrent oral 
ulcers, pharangitis, oesophagitis, pepticulcer, ascites, hepatomegaly 
(50%), transaminitis (20%)18.  
BuddChiari Syndrome, lupoidhepatitis, pseudo intestinal obstruction, 
mesenteric vasculitis, protein loosing enteropathy, peritonitis, pancreatitis (4%), 
biliarycirrhosis, cholangitis and cholecystitis have also been reported19. 
 13
5.  Cardiovascular: Pericarditis including pericardial effusion in 
30% to 45%, myocarditis in 5-10%, endocarditis15%, Libman-sack’s in 
2-5% and valvular heart disease AR & MR 18-74% are seen8,9,11,24.  
Lagana et al, 1999 studied autonomic dysfunction to be associated 
with microvascular disease or metabolic alteration.  
Coronary artery heart disease is seen as an effect of 
accelerated atherosclerosis in patients even < 35 years because of 
steroid induced dyslipidemia, hypertension and immune complex 
mediated intracellular cholesterol accumulation20,21. The 
microcirculation can be affected by vasculitis, APLS, Raynaud’s and 
atherosclerosis. 
Pulmonary hypertension can be seen as a reversible entity. When 
it is secondary to ILD it is of severe type with irreversible changes of 
the capillary bed. Pulmonary capillaritis and plexogenic arterial 
transformation has been reported with poor prognosis. Pulmonary 
embolism and acute reversible hypoxemia has been reported. Raynaud’s 
phenomenon is seen in 75% of patients with SLE and pulmonary 
hypertension. There is high incidence of anti U1 RNP, rheumatoid factor 
and APL antibody in patients with pulmonary hypertension11. 
6.  Pulmonary involvement: SLE can involve any part of the 
respiratory system22,23. Upper Airway involvement is seen in 10-15% of 
SLE and the manifestation are epiglottitis, subglottic stenosis, vocal 
cord paralysis, laryngeal oedema or ulceration, inflammatory mass 
lesions or nodules, cricoarytenoid arthritis and as necrotising vasculitis. 
Pleural Disease is seen in 36% of the patients. About 38% to 40% of 
patients with normal chest x-ray have abnormal CT findings12. 
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Parenchymal Disease is seen in 7% as acute lupus pneumonitis, 
alveolar haemorrhage syndrome, chronic interstitial lung disease, 
lymphocytic interstitial pneumonia (LIP), Bronchiolitis obliterans with 
or without organising pneumonia. Acute reversible hypoxemia in lupus 
pneumonitis is due to increased levels of complement split products that 
activate neutrophils which aggregate within pulmonary vasculature 
causing decreased oxygenation capacity which resolves with steroids. 
Alveolar haemorrhage and acute lupus pneumonitis are life threatening. 
Shrinking lung syndrome was described by Hoff brand in 1965. This is 
due to diaphragmatic weakness, basal pleural or pulmonary fibrosis and 
primary myopathy, disease activity and phrenic nerve involvement13. 
Chest X-ray shows progressive elevation of diaphragm with normal 
parenchyma. Normal corrected Carbon monooxide transfer with 
restrictive pattern in PFT is characteristic feature of this condition23.  
7.  Hematologic Features : Anaemia of chronic disease is seen in 
60-80%, autoimmune haemolytic anaemia (AIHA) in 10% with positive 
Coomb’s test in 20-60%. Leukopenia seen in 30% is associated with 
neutropenia or lymphopenia; generally between 2500-4000/mm3 and is 
associated with active disease. Thrombocytopenia is seen in 30-50% and 
is related to antiplatelet antibody or APL antibody. Immune 
thrombocytopenia (ITP) is seen in 5–10% of SLE cases at the onset of 
disease. ANA positivity in ITP is about 15-20%. Other antibodies seen 
are those to factor II, VIII, IX, XI or XII, protein C, S and antithrombin 
III. Pancytopenia is seen in 2-4% of the cases at the onset8,9,11. 
Anecdotal reports of TTP have been reported.  
Nescher et al in his study reported 28 SLE patients associated 
with TTP. Dubois et al reported that TTP can follow SLE by several 
years or occur concurrently with SLE and rarely antedate the onset of 
SLE.  
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Tzioufas AG et al 1997 found 15.2% patients to have antibody to 
erythropoietin and it was associated with anaemia and active disease. 
AL-Shahi R et al 1997, discovered platelet CD36 glycoprotein antibody 
which produced severe thrombocytopenia and microangiopathic 
haemolytic anaemia (MAHA).  
Splenomegaly is seen in nearly 30% of childhood SLE and about 
20% in adult onset. Lymphadenopathy is seen in 60% at the onset and 
usually subsides with treatment6.  
Anti Phospholipid Antibody Syndrome and SLE 
Secondary APL in SLE is characterised by the presence of APL 
antibody (+ve ELISA for IgG/IGM ACL antibody / +ve LAC/BFP test 
for syphilis), recurrent arterial / venous thrombosis, fetal loss and 
thrombocytopenia. Association has been seen with livedoreticularis, 
cerebral disease (CVA, TIA, chorea, amaurosis fugax) and pulmonary 
hypertension. Persistent false positive VDRL is seen in various SLE 
studies as 10-20%.  LAC can be detected by diluted russel viper venom 
test, kaolin clotting time and complete activated partial thromboplastin 
test with three steps procedure. In SLE, ACL is positive in 50% of LAC 
positive cases but LAC is positive only in 20% of ACL positive cases. 
In catastrophic APLS, the ACL antibodies may be negative because it is 
used up in the consumption25. 
Pathogenesis 
Endothelial injury precedes non-inflammatory vascular occlusion. 
Antibody are directed against a co-factor. β2 glycoprotein-I sushi 
domain, which on binding to phospholipid template undergoes a 
conformational change and triggers off the coagulation cascade. The 
 16
antibodies are  directed against phospholipids , prothrombin, protein C, 
protein S and thrombomodulin29,30,31,32,33.  
8.  Renal lupus: Cameroon while analyzing 365 renal biopsies 
found Type 1 in 6%, Type 2 in 19%, Type 3 in 23%, Type 4 in 43%, 
Type5 in 9% and Type6 in 1%. Bhuyan et al 15 observed among 85 SLE 
Indian patients, 65% had renal involvement, with hypocomplementemia 
and high dsDNA activity. Chandrasekharan et al 16 reported 37% renal 
involvement among 170 patients. Renal lupus is found in 50-70% of 
patients during the disease course6,8,10. WHO classification of lupus 
nephritis Plate 3.  
Type of lesion Microscopic findings 
0 - Normal glomeruli A- Nil 
B - Deposit in EM/IFT 
1 - Pure mesangial  A - Mesangial widening & mild 
hypercellularity 
B – Moderate hyper cellularity 
2 - FSGN  A - Active necrotizing  
B - Active and sclerosing lesions  
3 - FPGN A - Active necrotizing 
B - Active and sclerosing lesions 
4 - Diffuse GN A - Without segmental lesion 
B - With activenecrotising lesion 
C - With active and sclerosing lesion  
D - Sclerosing lesions 
5 - Diffuse membranous GN A - Pure membranous  
B - Class II + membranous 
C - Class III+ membranous 
D - Class IV+ membranous 
6 - Advanced sclerosing GN Sclerosing Glomeruli 
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Immunopathogenesis in renal lupus is due to antidsDNA and 
antihistones antibodies, which get complexed with the polyanionic 
glycoprotein in the glomerular ground substance. Along with the antigen 
antibody complex, IgG, IgM, IgA, C1, C3 and fibrinogen get deposited. 
The renal activity scoring is used by the NIH from the work of Austin et 
al. Activity is scored as 4 grades (glomerular proliferation, necrosis-
karyorrhexis, hyaline thrombi, cellular crescents, leukocytic exudation, 
monocytic infiltration in the tubules) a total of 24 and chronicity is 
scored as (sclerosing glomeruli, fibrous crescents, tubular atrophy and 
interstitial fibrosis) as 3 grades with a total of 12. Renal involvement is 
nearly 100% in the course of the illness and hence renal biopsy is 
mandatory13,26,29.  
Many studies on SLE, have reported that hydroureteronephrosis, 
mega ureters, sterile cystitis and bladder dysfunction were seen9,15.  
9. Neuropsychiatric: Twenty six percent (Dubois et al) of SLE 
patients manifest NP features29. The 1999 ACR Nomenclature 
Committee identified 19 different NP conditions that are part of the 
lupus complex 12 with CNS and 7 with PNS. They are headache, 
cognitive dysfunction, mood disorder, acute confusion state, psychosis, 
seizures, aseptic meningitis, demyelinating syndrome, movement 
disorder, stroke syndromes, transverse myelitis, GullianBarre like 
inflammatory demyelination, myasthenia gravis, autonomic neuropathy, 
cranial and peripheral neuropathy. Anti sm antibody is with neurosis and 
anti RNP is seen with psychosis. The other antibodies seen are anti 
neuronal, anti lymphocyotoxic, anti myelin, antibodies to the 
neurotransmitter and receptors. CT scan and MRI scan will enable to 
delineate the exact area involved, but for neuronal function PET studies 
are helpful30,31 Plate 4. 
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Eye manifestation are conjunctivitis, iritis, choroidal and retinal 
vasculitis, glaucoma, cataract, opticneuropathy, papilloedema, 
cytoidbodies (pathologically they represent fibrinoid degeneration of the 
nerve terminals), macular degeneration, orbital myositis and 
ophthalmoplegia. SLE can present at the onset with the retinal vasculitis 
in 3-4% of the cases32. 
SLE can involve the external ear in sec. APLS, vasculitis 
involving the tympanum, middle ear, semicircular canals and as 
sensorimotor or conduction deafness.  
PREMATURE ATHEROSCLEROSIS IN SLE 
Atherosclerosis is an active inflammatory and immune mediated 
disease32,33,34,35. Immune complex formation, complement activation, 
upregulation of CD 40-40L interaction (between B and T cells), C 
reactive protein and APLS cause endothelial injury and local 
inflammation and LDL uptake by endothelial cells. Hyper 
triglceridemia, hypertension and renal disease adds on to the 
atherosclerosis burden. Among Asians there is higher insulin resistance 
producing hypertriglyceridemia and low density lipoproteinemia, 
lowered HDL, procoagulant tendency, increased proinflammatory 
cytokines and endothelial dysfunction which lead on to early 
atherosclerosis. This has been observed in other studies 37,38,39.  
DEVELOPMENT OF THE PLAQUE 
The stages through which plaque evolves are 1) Leukocyte 
recruitment, adhesion molecule upregulation along with increased 
homocysteine levels resulting in endothelial injury. 2) The smooth 
muscle cell and the fibroblast transform into foam cell by taking up the 
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LDL components. This phenomenon is favoured by impaired lipoprotein 
lipase, ↑ apolipoprotein B, ↓HDL3, ↑HDL 2 and ↑ serum lipoprotein (a) 
levels. The latter component is increased in lupus nephrotic syndrome. 
Complement fixing antibody inhibit 27 (OH) cholesterol which down 
regulates LDL receptors. β2glycoprotein-1, oxidized LDL, M-CSF, 
MCP-1, TNF-α, help in the proliferation of macrophage and elaboration 
of tissue factor enabling increase plaque formation 3) Finally the plaque 
ruptures40,41,42. 
Joanne McDonald et al. in his study reported that coronary artery 
involvement depends on SLE duration, usage of steroids and 
atherosclerosis at other sites. 
The assessment of vascular disease can be done by Duplex 
Doppler of the carotids looking for plaque as a marker and 
measurement of intimo medial thickness as a surrogate marker of 
diffuse atherosclerotic process. One can measure IMT, peak systolic 
velocity, end diastolic velocity, waveform, plaque, compliance, 
dispensability, stiffness index, stenosis and elastic incremental 
modulus43.  
Theodoridu A et al58 measured ankle branchial index by using 12 
cm cuff and 8MHz Doppler probe and found that if the ratio is <1 then 
there is vascular compromise in the peripheral vessel. This is picked up 
in the late stage of atherosclerotic disease.  
Pigouli et al44 demonstrated in 1980’s that Doppler U/S can be 
used for carotid measurement. The double line pattern correlated with 
the intimo medial thickness seen in histopathology. The positive 
predictive value and negative predictive value for categorization of 
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stenosis >50%diameter reduction was seen more accurate by B mode 
ultrasound. 
IMT is the distance between lumen –media interface and 
media-adventitia interface.  
Cholesterol lowering and atherosclerosis study (CLAS) study 
showed that the relative risk for MI and coronary death was 3.1 for each 
0.03 mm /yr (1 SD) ↑ in mean CCA IMT25.  
Cardiovascular health study (CHS) showed in 5888 non 
smoking males aged 40-59yrs who had undergone previous CABG, were 
observed to have an increased risk of stroke and MI for each 
0.2mm/yr(1SD) of intimo medial thickness34. Thus in several studies it 
was highlightened that Duplex Doppler measurement provide valuable 
information about the genesis and progression and atherosclerosis. 
The morphology appreciated in Doppler U/S is as follows, 
Stage I-normal wall, 
Stage II- wall thickening (stenosis with out plaque), 
Stage III- non stenosing plaque, 
Stave IV- stenosing plaque. Death occurs in stage III&IV events.  
The other type of classification of stages of plaque along with 
scoring is from A to F which was devised Backero G et al. in 1995. 
Class A: Normal, 3 US layers clearly separated. No disruption of 
lumen-intimal interface for at least 0.5 cm - Score (0). 
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Class B: Interface disruption: lumen-intimal interface disruption  
at intervals < 0.5 cm - Score (2). 
Class C: Intima-media granulation: granular echogenicity of deep, 
normally unechoic intimal-medial layer - Score (4). 
Class D: Plaque without hemodynamic disturbance: wall 
thickening and increased density involving all US layers. No 
hemodynamic disturbance on duplex - Score (6). 
Class E: Stenotic plaque: as in D but with hemodynamic 
disturbance on duplex - Score (8). 
Class F: Stenotic plaque and presence of symptoms - Score (10). 
Studies in SLE 
Among 229 SLE patients, in 1992 Petri et al.44 studied the 
frequency and risk factors of CAD. He found that a 0.2mm increment of 
IMT in CCA and 0.5mm in ICA IMT, increases the risk of CAD.  
Mansi et al.45 in 1999studied the prevalence and risk factors of 
carotid plaques in females with SLE and saw that mean IMT was 
0.71+0.14, for plaques.  
Rahman et al.46 in 2000 studied vascular events in SLE with 
hypertension. The factors that contributed were hypertension , azotemia, 
corticosteroid usage and hypercholestrolemia50.  
Fallaschie et al.47 in 2000, studied atherosclerotic events in the 
carotids and the risk factors in 26 childhood SLE patients. He found that 
below 16 yrs mean IMT is 0.5mm+0.05mm. IMT did not correlate with 
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age, disease duration, SLEDAI but did correlate with nephrotic range of 
proteinuria >3.5gm / 24 hrs and lipid profile63.  
Doria et al.50 study in 2003, of SLE patients showed that IMT 
reading of 0.9mm for thickened intima and of >1.3mm for 
atherosclerotic plaque was present as significant cut off limits.  
Duplex Doppler of carotid can be studied in comparison with 
other peripheral arteries also. Talia Wolak et al. in 2004 studied 51 
patients with SLE along with age and sex matched controls. High risk 
factors like hypertension was found in 30% smoking in 23% and 
dyslipidemia in 17%. A 3.17 fold of atherosclerotic plaque was found in 
the patients. 
Duplex Doppler can be used as a early diagnostic tool for 
detecting premature atherosclerosis. 
CERTAIN SPECIAL SITUATIONS 
Drug induced SLE is seen in Procainamide, isoniazid and 
hydralazine commonly. CNS, renal disease, leukopenia, mucocutaneous 
ulcers and anemia are rare. Antihistone Ab’s are positive in 100% of 
drug induced SLE patients Recently usage of TNF α blockers show 
ANA positivity of 10-15%, and is reversible with drug withdrawal9,31.  
LUPUS IN MALES 
World wide reports on male SLE patients reveal that the onset is 
with fever, and milder skin manifestation. Chellapandian et al60 in a SI 
study observed renal involvement, recurrent infections and coronary 
artery disease were seen more and malarrash, serositis, neuropsychiatric, 
leukopenia and thrombocytopenia were seen with lesser frequency. 
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 Prognosis is worse. Fifty percent of patients in one study series 
had elevated plasma estrogen levels (Miller et al, 1980), hence 
individuals with Klinefelter’s syndrome are more susceptible to develop 
SLE15,16.  
Late onset LUPUS 
Chandrasekharan et al8,9 had observed in his study that, there 
was less female preponderance and musculoskeletal and haematological 
manifestations were more than renal, serositis and CNS involvement.  
Lupus beyond 50 years represents 10% of study population. There 
is a lesser frequency of anti dsDNA Ab & decreased C 3/C4. Overlap 
between lupus and Sjogren’s is common. Polymyalgia rheumatica like 
presentation can occur16.  
Pregnancy and Lupus 
Fertility is normal in SLE patients (exception - renal failure is 
associated with decreased fertility). Dysmenorrhea, amenorrhoea or 
oligomenorrhea is common in active disease. 28-40% of pregnancy 
wastage is seen as spontaneous abortion, still birth and perinatal deaths. 
Fetal loss is due to active disease, APLS or active lupus nephritis. APLS 
is associated with IUGR, PET and preterm delivery51.  
Neonatal lupus syndrome is associated with 20% maternal anti 
Ro/La antibodies, thrombocytopenia, rash and congenital heart block. 
Indicators of activity are elevated anti ds DNA levels, alternative 
pathway hypo complementemia, true arthritis, rash, mucosal ulcers and 
lymphadenopathy6,52.  
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Johns KR et al in 1998 studied pregnancy outcome in 54 cases and 
found mean gestational age for live births to be 36 weeks and mean birth 
weight to be 2.4 - 3 kg. He found that renal flares had a worse outcome.  
LUPUS AND MALIGNANCY 
According to studies by John H. Klippel et al; in 1995, 
documented an increased risk for lymphoma and soft tissue sarcoma. 
Malignant lymphoma and macroglobulinemia is due to prolonged 
antigenic stimulation of B-lymphocytes.  
ANA NEGATIVE LUPUS 
True ANA negative cases comprise less than 2%. Several reports 
have stated the delayed appearance of ANA. A negative ANA can 
become positive by merely using another substrate, e. g. with HEp-2cell 
line shows that 98% are ANA positive because non DNA containing 
antigens Ro/SS-A are better represented when these cell lines are 
studied (Reischllin et al) The causes for ANA negativity are pro zone 
phenomena, invivo binding of ANA by tissues, ANA hidden within 
circulating immune complexes, variations in microscope quality, 
substrate specificity, use of monospecific antisera, technical inaccuracy 
and low cut off dilutions. ANA negativity is seen in Primary APL 
antibody syndrome, early disease, previously positive ANA made 
negative by steroids, cytotoxic drugs or uremia.  
Childhood onset SLE: In children the sex ratio is nearly F:M 2:1 
(<12 yrs) and 6-7:1 (> 12 yrs). Tucker et al10 compared childhood SLE 
to adult SLE and he observed that the onset was more severe and the 
hematological, renal complications were frequent while 
cardiopulmonary diseases were more common in adult onset group. Anti 
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ds DNA, anti Sm, anti RNP and decreased C3 were more frequently 
observed in childhood SLE.  
The treatment have to be individualized and depends on organ 
involvement and disease flares. Steroid is still mainstay of treatment.  
Morbidity and mortality in SLE depends on the systems involved 
(renal, neuropsychiatric, cardiovascular, ILD, PHT), age of the onset of 
the disease and infections. It has been seen that in 1955, 5 yr survival 
was 50%, in 1990 10 yr survival has risen to >90% and 20 yr to 70% and 
mortality 3-5 times greater than general population. 
Joshi et al55 in his boot’s oration 1994, reported that SLE in 
pediatric age group is severe and infections still form a considerable 
cause (next to renal and CNS) for the mortality in developing countries.  
Lupus activity can be periodically assessed by indices like 
SLEDAI, (appendix 2). It is scored by events which has occurred 10 
days prior. Twenty four items involving 9 systems are scored from 1 to 
8 (Appendix 3). 
Mex-SLEDAI was devised for the developing countries wherein 
the investigation (immunology and complement assay) have been 
removed and scoring involves only clinical assessment and simple tests. 
BILAG is a grading system from a to d. SLAM measures 32 items of 11 
organs where the degree of severity is recorded as 0-3.  
SLICC / ACR DI is a damage assessment index wherein damage 
that has occurred in the last 6 months is scored (Appendix 4). 
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MATERIALS AND METHODS 
One hundred consecutive patients who attended the Rheumatic 
care center, Government General Hospital, Madras Medical College, 
Chennai and satisfied the revised 1982 ACR criteria for SLE, during 
2003 January to 2004 December were selected out of 12,786 adult and 
2282 childhood Rheumatic cases. 68 were adults and 32 were children.  
A detailed history was documented and after clinical examination 
(Appendix 2) they were subjected to laboratory investigations which 
included complete blood count, erythrocyte sedimentation rate, 
(Westegren method) serum creatine, blood urea, urine analysis, muscle 
enzymes and 24 hrs urine analysis. Immunological tests include tests for 
ANA by IIF on rat liver substrate, RF & CRP by latex agglutination 
method by using commercial kits provided by Vital Diagnostics, 
Chennai. Antibodies to dsDNA, Sm, Ro, La, U1RNP, ACL was done by 
ELISA using commercial Bindazme company kits. LAC was done by 
Activated partial thromboplastin method complete test with three step 
procedure, using commercially obtained APTT substrate. The significant 
cutoff values for the positivity of the various antinuclear antibodies had 
already been determined in our lab with respect to healthy controls. C3, 
C4 were quantitated by single radial immunodiffusion (SRID) using 
Diffusa plates from Bioscientifica. The cut of values taken were (C3-70 
mg/L, C4-20 mg/L). Serological test for syphilis were performed by the 
VDRL test in the Institute of Sexually transmitted diseases, M.M.C.  
All patients underwent a 12 lead ECG, skiagram of the chest and 
relevant areas. Patients were subjected for 2D echocardiogram and 
doppler study by cardiologist. Laboratory evidence of renal involvement 
was noted and renal biopsy was done. Renal biopsy was subjected to 
light and immunofluorescent microscopy. Special tests like EEG, EMG, 
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CT scan, MRI, EMNCS, Bone marrow, CSF analysis were done in 
relevant situations. The clinical, immunological profile of childhood and 
adult patients were analysed and compared with previous studies in 
India.  
The study population for Duplex Doppler evaluation was drawn 
from the previous sample. Patients who were non compliant to the 
instruction were not included. The sample contained 20 children and 30 
adults who were evaluated for subclinical atherosclerosis. 
A information on the age, disease duration, smoking, family 
history of atherosclerosis disease previous diabetic state, steroid usage 
and presence of hypertension was noted. SLEDAI scoring was done at 
the point when patients were subjected to Doppler ultrasound. 
BP in adults above 140/90mmHg, in children 120/80mmHg was 
taken as cut off value. The laboratory variables like the haemoglobin 
(Hb) Total count (TC), platelet (Pt), blood glucose, chest X-ray (CXR), 
LAC, ACL, anti dsDNA, C3, C4 were noted. Estimation of lipid profile 
was done on fasting serum sample in these patients. 
Colour Doppler interrogation of the carotid arteries at the 
level of CCA, carotid bulb, ECA, ICA using a 8.5 MHz probe by a 
experienced Radiologist. 
The parameters like intimomedial thickness (IMT), stenosis, peak 
systolic velocity, end diastolic velocity, wave form and presence of 
plaque were studied. Presence of the parameters was taken as 1 and 
absence of the parameter was taken as 0. 
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The cut off values for the laboratory variables was taken as follows: 
1. Haemoglobin-children 12mg%, adults 10gm% 
2. Total count - 4000/ mm3 
3. Platelet - 1lakh / mm3 
4. Total cholesterol <200 mg%, 
5. LDL cholesterol < 100 mg%, 
6. HDL cholesterol 40 mg%, 
7. Triglycerides <150 mg% 
8. Lupus pneumonitis in CXR-presence as 1, absence as 0 
9. Complements -C3 or C4 normal as O, reduced levels as 1 
The LDL was calculated by Friedwald equation: 
LDL cholesterol=Total cholesterol-(HDL cholesterol+1/5 Triglycerides). 
TC/HDL, LDL/HDL ratios were calculated. 
The doppler parameters given below were analysed with variables 
like LAC, ACL, anti ds DNA, C3, C4, CXR, haemoglobin (Hb), total 
count (TC), platelets, (pl), lipid components (TCl, HDL, LDL, TGL) and 
TCl/HDL, LDL/HDL ratios. 
(I) 1. IMT 
     2. Plaque formation 
     3. Spectral widening 
     4. Stenosis  for laboratory variables. 
(II)1. IMT 
     2.  Plaque for risk factors (Traditional and related to SLE disease). 
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COLOUR DUPLEX DOPPLER OF CAROTIDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31
STATISTICAL ANALYSIS 
The clinical profile of the patients were analysed using 
descriptive statistics like mean, median, percentages for the different 
characteristics.  
Analysis of the lipid profile and the Duplex Doppler of the 
carotids was done. Descriptive statistics like mean, standard deviation 
were calculated for continuous variables, while percentages were 
calculated for categorical variables. Chi-square test was done to 
determine association between two categorical variables. Student’s t test 
was used to test for significant difference between two means. Pearson’s 
correlation was calculated to determine association between two 
continuous variables. Renal involvement was analysed with Mann-
whitney U test and Kruskal-Wallis test. Significance was determined at 
5%. Statistical analysis was done using SPSS Ver. 11.0. Graphs were 
produced using Microsoft Excel. 
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RESULTS 
Among 32 children there were 4 male and 28 female children, M: 
F 1:7. The mean age in childhood onset SLE was 12.6 years (range 6.5-
16 yrs) and mean disease duration 1.2 years (1 month - 2.6 years). There 
was no child below 5 years in the study group. The observed sex ratio 
below 10 years was M:F = 1:4.2 and between 10 to 16 years was 1:10.  
Among adults there were 4 males and the sex ratio was M:F=1:17. 
In the adult onset SLE the mean ages was 28 years (17-42 yrs) and the 
disease duration was 1.18 years (3 months - 3.6 years). 
The results have been tabulated as initial manifestation and cumulative.  
Table 1: INITIAL MANIFESTATION 
Clinical features Child n= 32 
Adult 
n=68 
Fever 65% 10% 
Cutaneous 48% 70% 
Arthritis 45% 51% 
Renal 9.3% 7.3% 
Haemolytic anaemia 12.5% 3.2% 
Thrombocytopenia 12% 6.2% 
Seizures 6.2% 2.9% 
Pleural effusion 3% 17.6% 
Pericardial effusion 3.1% 20% 
Ascites 3% 20.5% 
Lymphadenopathy 62% 36.6% 
 
In children among the initial manifestations, fever was a 
prominent feature in 65%, followed by arthritis and cutaneous 
involvement. Adults had cutaneous more pronounced along with 
photosensitivity and alopecia.  
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CUMULATIVE MANIFESTATION: 
1. Muco-cutaneous 
 
 Child Adult 
Cutaneous 52% 75% 
ACLE 65% 62% 
SCLE 1% 28% 
DLE 1% 5.8% 
Oral ulcer 44% 68% 
Photo sensitivity 54% 72% 
Raynauds 6.25% 13.2% 
Digital gangrene 2.9% 7.3% 
Urticaria 2.9% 5.8% 
Dyschromia 22% 65% 
Alopecia 48% 57% 
Fever 82% 65% 
 
2. Musculoskeletal 
 
 Child Adult 
Arthralgia 76% 82% 
Arthritis 52% 58% 
AVN 12.5% 4.4% 
Jaccouds 12.5% 13.2% 
 
3. Reticuloendothelial 
 
 Child Adult 
Hepatomegaly 55% 9% 
Splenomegaly 25% 20% 
Lymphadenopathy 55% 25% 
 
4. Cardiovascular 
 
 Child Adult 
MVPS 6.2% 4% 
MR 3% 2.9% 
Pericardial effusion 18.7% 14.7% 
Myocarditis 3% 2.9% 
Libman-sach’s Nil Nil 
IHD Nil 1.4% 
PHT Nil 5.8% 
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5. Pulmonary 
 Child Adult 
Pleural effusion 31.2% 17. 64% 
Pneumonitis 9.3% 5. 8% 
Pulmonary-haemarrhage 3% Nil 
ILD Nil 2. 9% 
Shrinking lung Nil 1. 4% 
 
6. Gastrointestinal 
 Child Adult 
Ascites 6.5% 7.2% 
Pancreatitis nil 4% 
Enteritis 6% 12% 
 
7. Renal Biopsy 
WHO 
Classification 
Child 
Total 18.6% 
Adult Total 
16.2% 
Class I - - 
Class II 3.1 4.4% 
Class III 3.1% 2.9% 
Class IV 6.2% 7.3% 
Class V 6.2% 1.4% 
 
8. Renal manifestation 
 Child 
Total 65% 
Adult Total 
44% 
Proteinuria 46% 60% 
Haematuria  21% 26% 
Casturia  9.3% 26% 
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9. Neuropsychiatry 
CNS manifestations Child 
Total 37.5% 
Adult 
Total 36% 
Seizures 30% 5.2% 
EEG 12.5% 8.8% 
CVA Nil 2.9% 
PNS 2.9% 4.4% 
Chorea Nil Nil 
Spinalcord Nil 1% 
Eye 9.3% 7.3% 
Psychiatry 31.2% 36.7% 
 
10. Muscular system 
 Child Adult 
Myositis 6% 8% 
Muscle enzyme 21% 17. 8% 
EMG 15% 22% 
 
11. Investigation  
Laboratory Child Adult 
Anaemia-haemoglobin 56% 51.4% 
Coombs 12.5% 11.7% 
Thrombocytopenia7 18.7% 22% 
TTP Nil Nil 
Leukopenia 15% 8.8% 
Lymphopenia 3% 2.9% 
MRI 3% 1. 4% 
CT scan 3% 5.8% 
ANA (negative) 2.9% 4.4% 
ANA (positive) 97.1% 95.6% 
ds DNA 65.6% 51.4% 
ACL 16% 13% 
LAC 9.3% 8.8% 
C3 18.75% 13-20% 
C4 3.75% 3.5% 
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12. Muscular system 
Lipidlevels Child n= 25 Adult n=60 
↓HDL 3 
N 22
12 
N 48 
↑LDL 5 
N 20
10 
N 50 
↑Total Cholesterol 5 
N 20
16 
N 44 
↑Triglycerides 8 
N 17
28 
N 32 
 
N= normal 
Treatment Child Adult 
Methylprednisolone 21% 30% 
Oral Prednisone Low dose 
High dose 
46% 
53% 
47% 
52% 
Chloroquine > 10 years 25% 91% 
Azathioprine 12.5% 16% 
Cyclophosphamide 18.75% 22% 
Methotrexate 1.4% 2.9% 
Anticonvulsants 15.6% 16.1% 
Acitrom 9.3% 15.2% 
Antihypertensives 15.6% 22.05% 
Antidepressants 1% 36% 
Aspirin 9.3% 36% 
Atorvastatin 1% 7.3% 
ATT Nil 2.9% 
Antianginal Nil 4.4% 
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One of the complications in SLE is recurrent infection. It was 
seen in 12.5% in children and 7.3% in adults. 
The statistical observations between parameters of Duplex 
Doppler and components of lipid profile (TCl, HDL, LDL, TGL), 
haemoglobin, complements, anti dsDNA, LAC and ACL and the risk 
factors are given in the tables below.  
PARAMETERS OF DUPLEX DOPPLER AGAINST VARIABLES 
CHILDREN 
Table1: Plaque Vs variables 
Variables 0 (n = 18) 
1 
( n = 2 )  p value* n % n % 
LAC 1 33.3 2 66.7 0.02 
ACL 1 50.0 1 50.0 0.19 
ANA 18 90.0 2 10.0 - 
Ds_dna 9 81.8 2 18.2 0.48 
C3_C4 4 66.7 2 33.3 0.08 
CXR 2 100.0 - - 1.00 
* Chi-square test 
Table 2:Plaque 
Variabl
es 
0 (n = 18) 1 ( n = 2 ) p value* Mean SD Mean SD 
Hb 8.9 1.9 8.7 2.1 0.88 
TC 7622.2 3771.8 6700.0 707.1 0.74 
Pt 1.9 0.8 1.6 0.3 0.64 
TCL 161.7 31.1 162.0 36.8 0.99 
HDL 40.4 8.2 38.0 8.5 0.69 
LDL 101.5 31.6 101.0 18.4 0.98 
TGL 155.2 75.0 167.0 60.8 0.83 
* Independent t-test 
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Table 3: Stenosis 
Variables 0(n = 10) 1( n = 10 )  
p value* n % n % 
LAC - - 3 100.0 0.21 
ACL - - 2 100.0 0.47 
ANA 10 50.0 10 50.0 - 
dsDNA - - 7 63.6 0.37 
C3 C4 1 16.7 5 83.3 0.14 
CXR 2 100.0 - - 0.47 
* Chi-square test 
Table 4: Stenosis 
Variables 0(n = 18) 1 ( n = 2 )  
p value*Mean SD Mean SD 
Hb 8.9 1.9 8.7 2.1 0.88 
TC 7622.2 3771.8 6700.0 707.1 0.74 
Pt 1.9 0.8 1.6 0.3 0.64 
TCL 161.7 31.1 162.0 36.8 0.99 
HDL 40.4 8.2 38.0 8.5 0.69 
LDL 101.5 31.6 101.0 18.4 0.98 
TGL 155.2 75.0 167.0 60.8 0.83 
* Independent t-test 
Table 5: Spectralwidening 
Variables 0 (n = 18) 1( n = 2 ) p value* 
n % n % 
LAC 1 33.3 2 66.7 0.02 
ACL 1 50.0 1 50.0 0.19 
ANA 18 90.0 2 10.0 - 
ds DNA 9 81.8 2 18.2 0.48 
C3C4 4 66.7 2 33.3 0.08 
CXR 2 100.0 - - 1.00 
* Chi-square test 
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Table 6: Spectralwidening 
Variables 
0
(n = 10)
1
( n = 10 )  p value*Mean SD Mean SD
Hb 9.7 2.0 8.1 1.5 0.06
TC 8010.0 4263.1 7050.0 2900.3 0.56
Pt 1.8 0.8 1.9 0.9 0.54
TCL 149.7 23.9 173.8 32.8 0.08
HDL 39.4 5.8 41.0 9.9 0.67
LDL 89.0 22.3 113.9 32.8 0.06
TGL 109.6 56.5 203.2 54.9 0.001
* Independent t-test 
Table 7: IMT 
Variables n Mean Standard Deviation p value* 
LAC 
       0 
       1 
 
17 
3 
0.43 
0.50
0.11 
0.16
0.30 
ACL 
      0 
      1 
 
18 
2 
0.43 
0.49
0.11 
0.22
0.75 
ds DNA 
     0 
     1 
 
9 
11 
0.42 
0.45
0.09 
0.13
0.57 
C3 C4 
     0 
     1 
 
14 
6 
0.41 
0.51
0.11 
0.10
0.06 
CXR 
     0 
     1 
 
18 
2 
0.44 
0.47
0.12 
0.01
0.74 
* Independent t-test 
Table 8: Correlation with IMT 
Variables Correlation Coefficient P value 
Hb -0.40 0.08 
TC -0.26 0.27 
PT -0.08 0.73 
TCL 0.29 0.21 
HDL -0.08 0.73 
LDL 0.27 0.25 
TGL 0.51 0.02 
TCL:LDL 0.395 0.09 
LDL:HDL 0.384 0.10 
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ADULTS 
Table 1: Plaque 
Variables 0 (n = 27) 1( n = 3 )  
p value N % n % 
LAC 7 70.0 3 30.0 0.03 
ACL - - 1 100.0 0.002 
ANA 27 90.0 3 10.0 - 
ds DNA 7 87.5 1 12.5 1.00 
C3 C4 9 90.0 1 10.0 1.00 
CXR 4 100.0 - - 1.00 
 
Table 2: Plaque 
Variables 0 (n = 27) 1 ( n = 3 )  
p value Mean SD Mean SD 
Hb 8.8 1.9 7.3 1.8 0.22 
TC 7103.7 1754.0 6900.0 2805.4 0.86 
Pt 1.8 0.8 1.9 0.9 0.82 
TCL 178.2 40.2 211.0 13.0 0.18 
HDL 41.7 4.8 42.7 6.4 0.76 
LDL 109.9 32.0 139.0 21.4 0.14 
TGL 132.1 73.6 187.7 25.1 0.21 
 
Table 3: Stenosis 
Variables 0(n = 10) 1 ( n = 20 )  
p value n % n % 
LAC 2 20.0 8 80.0 0.42 
ACL - - 1 100.0 1.00 
ANA 10 33.3 20 66.7 - 
ds DNA 3 37.5 5 62.5 1.00 
C3C4 5 50.0 5 50.0 0.23 
CXR 2 50.0 2 50.0 0.58 
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Table 4: Stenosis 
Variables 0 (n = 22) 1 ( n = 8 )  
p value Mean SD Mean SD 
Hb 8.8 2.0 8.1 1.7 0.41 
TC 7072.7 1742.5 7112.5 2150.4 0.96 
Pt 1.9 0.8 1.6 0.6 0.35 
TCL 168.9 36.9 216.0 22.8 0.002 
HDL 41.5 4.8 42.8 5.5 0.55 
LDL 103.8 28.3 137.6 30.1 0.008 
TGL 116.1 55.1 197.1 83.0 0.004 
 
Table 5: Spectral widening 
Variables 0 (n = 22) 1 ( n = 8 ) p value 
n % N % 
LAC 6 60.0 4 40.0 0.38 
ACL - - 1 100.0 0.27 
ANA 22 73.3 8 26.7 - 
dsDNA 5 62.5 3 37.5 0.64 
C3C4 9 90.0 1 10.0 0.21 
CXR 4 100.0 - - 0.55 
 
Table 6: Spectral widening 
Variables 0 (n = 10) 1 ( n = 20 )  
p value Mean SD Mean SD 
Hb 8.7 2.0 8.5 1.9 0.79 
TC 7370.0 1606.3 6940.0 1938.4 0.55 
Pt 1.9 1.1 1.7 0.6 0.59 
TCL 154.4 23.8 195.0 39.2 0.006 
HDL 42.8 5.2 41.4 4.8 0.45 
LDL 89.2 17.5 124.7 31.4 0.003 
TGL 114.8 63.7 149.1 74.8 0.23 
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Table: 7 IMT 
Variables n Mean Standard 
Deviation 
p value 
LAC 
       0 
       1 
 
19 
9 
 
0.42 
0.42
 
0.08 
0.11
0.91 
ACL 
      0 
      1 
 
27 
1 
 
0.41 
0.52 
 
0.09 
- 
0.24 
ds DNA 
     0 
     1 
 
21 
7 
 
0.43 
0.38
 
0.09 
0.08
0.16 
C3C4 
     0 
     1 
 
19 
9 
 
0.44 
0.36
 
0.09 
0.07
0.02 
CXR 
     0 
     1 
 
24 
4 
 
0.43 
0.36
 
0.09 
0.07
0.14 
 
Table 8: Correlation with IMT 
Variables Correlation Coefficient P value 
Hb -0.04 0.83 
TC -0.11 0.58 
PT 0.15 0.43 
TCL 0.48 0.01 
HDL -0.21 0.29 
LDL 0.55 0.003 
TGL 0.24 0.21 
LDL:HDL 0.56 0.002 
TCL:HDL 0.52 0.005 
 
In children IMT was found to have positive correlation with TGL 
(P=0.02). Plaque was identified in 2 children and was found to 
significantly associate with LAC (p=0.02). Spectral widening positively 
associated with TGL (p=0.001). Stenosis was found to be associated 
with presence of LAC (p=0.02). 
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In adults IMT was found to positively correlates with 
TCl(p=0.01), LDL(p=0.003) and TCl/ HDL, LDL/ HDL ratios (p<0.05) 
Plaques identified in 3 adults were found to correlate with LAC(p 0.03) 
and ACL(0.002). Stenosis was found to correlate with TCl(p 0.002), 
LDL(p 0.008) and TGL (p 0.004). Spectral widening was found to 
correlate with TCl (p=0.006) and LDL (p 0.003).  
The scatter diagram and the box graphs pictorially represents the 
above results, where in the box graphs depict the mean and standard 
deviation.  
Comparison between Child and Adult 
 
ACL Vs IMT 
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TGL Vs Stenosis 
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Correlation of risk factors in SLE with plaque and IMT 
Table 1: Steroid usage 
 Children Adult 
Mean ± SD p value Mean ± SD p value 
No plaque 19.7 ± 7.4  
0.01 
16.5 ± 10.4 0.04 Plaque 35.0 ± 7.1 31.7 ± 20.2 
 
 Children Adult 
Correlation 
(r) 
p value Correlation 
(r) 
p value 
IMT 0.05 0.85 0.04 0.83 
 
 
 
 
 
 
Table 2: Age 
 Children Adult 
Mean ± SD p value Mean ± SD p value 
No plaque 14.2 ± 2.8  
0.39 
29.3 ± 7.1 0.88 Plaque 16.0 ± 2.8 28.7 ± 10.0 
 
 Children Adult 
Correlation 
(r) 
p value Correlation 
(r) 
p value 
IMT 0.51 0.02 -0.31 0.11 
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Table 3: Disease duration 
 Children Adult 
Mean ± SD P value Mean ± SD p value 
No plaque 18.3 ± 7.0  
0.99 
14.6 ± 9.4 0.38 Plaque 18.5 ± 24.7 20.0 ± 15.1
 
 Children Adult 
Correlation 
(r) 
p value Correlation 
(r) 
p value 
7IMT 0.16 0.49 -0.38 0.05 
 
 
 
 
 
Table 4: SLEDAI 
 Children Adult 
Mean ± SD p value Mean ± SD p value 
No plaque 18.8 ± 8.1  
0.25 
19.4 ± 12.1 0.72 Plaque 26.0 ± 5.7 16.7 ± 11.4 
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 Children Adult 
Correlation 
(r) 
p value Correlation 
(r) 
p value 
IMT 0.29 0.21 -0.28 0.15 
 
 
 
 
 
 
Table 5: Smoking and hypertension 
 
 
Variables 
Children Adult 
No Plaque 
(n = 18) 
Plaque 
( n = 2) 
P 
value 
No Plaque 
(n = 27) 
Plaque 
( n = 3 ) 
p 
value 
n % n % n % n % 
Smoking - - - - - 2 100.0 - - 1.00 
Hyperten-
sion 
5 83.3 1 16.7 0.52 9 75.0 3 25.0 0.05 
**Children 
Variables n IMT 
Mean 
 
Standard 
Deviation 
p value 
Smoking 
       0 
       1 
 
20 
- 
 
0.44 
-
 
0.12 
-
 
- 
Hypertensio
n 
      0 
      1 
 
14 
6 
 
0.42 
0.48 
 
0.12 
0.11 
 
0.37 
** Adult 
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Variables 
 
n 
 
IMT 
Mean 
 
Standard Deviation p value 
Smoking 
       0 
       1 
 
26 
2 
 
0.42 
0.41 
 
0.09 
0.09 
 
0.83 
Hypertension 
      0 
      1 
 
17 
11 
 
0.41 
0.43
 
0.08 
0.1
 
0.73 
 
Table 6: Renal 
  
Children 
Adult 
N Median 
(Range) 
p 
value* 
N Median 
(Range) 
p 
value*
No 
plaque 
18 0 (0, 5)  
0.35 
27 0 (0, 5) 
0.32 
Plaque 2 2.5 (0, 5) 3 2 (0, 5) 
* Mann-Whitney U test 
Renal 
 
Children 
Adult 
N Mean ± SD p 
value* 
N Mean ± SD p 
value* 
0 14 0.42 ± 0.09  
 
0.09 
 
 
11 0.43 ± 0.09 
0.29 
2 1 0.42 ± . 1 0.47 ± . 
3 1 0.20 ± . 1 0.53 ± . 
4 2 0.57 ± 0.12 4 0.33 ± 0.06 
5 2 0.57 ± 0.07 5 0.41 ± 0.09 
* Kruskal – Wallis Test 
IMT 
Child N20 Mean Std. 
Adult 30 0.4213 0.0854 
Total 50 0.4280 0.0982 
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DISCUSSION 
SLE is a well differentiated autoimmune connective tissue disease 
which affects all cell constituents during the progression of illness. Due 
to the advent of more effective treatment modalities there has been 
prolongation of life expectancy in these patients. 5 years survival is 90% 
and 10year survival is 70% in the developed world. They are prone for 
peripheral vascular disease also. This will further deteriorate the quality 
of life. 
Atherosclerosis is a diffuse process involving the coronary and 
the peripheral vessels including the carotids. 
There is a need to measure the atherosclerotic burden of the 
arteries in SLE patients. 
Although vasculitis and intra luminal thrombosis contribute 
significantly, the major component of long term changes in vessel wall 
is due to premature atherosclerosis. 
6-10% of the patients have clinical recognized premature 
atherosclerosis, when screening methods are used the prevalence rate 
may be even greater40% (42). 
Very few studies have been done on sub clinical atherosclerosis 
with vascular manifestation in SLE. 
Duplex Doppler is a cost effective non invasive procedure used to 
identify high risk atherosclerotic events. Intimo medial thickness and plaque 
detection are important parameters taken in various studies. In this study an 
attempt is made to correlate traditional and disease related risk factors with the 
Duplex Doppler parameters.   
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The clinical profile of the patients were compared to the Binoy J. 
Paul et al study (N K) 56 and Chandrasekharan et al (SI) 8, pertinent to 
the development of vessel wall disease. 
In this study, there was a preponderance of F: M ratio of 17:1 as 
compared to NK with 22:1. The mean age at onset was 28.4 and in NK, 
it was 26.2. The mean duration is 1. 4yrs in the NK and in this it was 1. 
2 years. This showed that SLE predominantly affects younger age group. 
Late onset SLE was not seen in this study.   
The clinical features at the initial onset were compared to the NK, 
and SI studies noted in the table below.       
Initial 
manifestation 
A.N.Chandrasekharan 
et al 
S I Study n=80 
1993 
Binoy. J. Paul et al 
N. Kerala Study n=75
2003 
Arthritis 70% 66.7% 
Cutaneous 51% 14.7% 
Renal 16% 6.7% 
Fever 52. 5% 4.0% 
Haemolytic 
anaemia 
NA 1.3% 
Thrombocytopenia 1. 2% 1.3% 
Chorea NA 1.3% 
Seizure NA 1.3% 
Pericardial 
effusion 
NA 2.7% 
 
Fout J.,Cerevera R. et al in 1998 compared childhood and adult onset 
SLE among 34 patients. He found that fever, lymphadenopathy and 
nephropathy more common in the children and on evolution of the disease 
malar rash, chorea and ACL positivity was seen. 
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At the initial onset, fever was a common presentation. Fever at the onset 
was commoner in children 65% than seen in adults (10%). In children there is 
always a presentation of prolonged fever with hepato splenomegaly which was 
seen in this present study also. Haemolytic anaemia presented as autoimmune 
haemolysis in 12.5% of children which was more common than adults (3.2%). 
Similarly the thrombocytopenic purpura, was seen in 12% of children again 
commoner than adults who had 6.2%. Serositis was seen in (58%) in adults 
which was more compared to children (9.1%). 
Seizures was seen more in children (30%) compared to (6.2%) in adults. 
The initial presentation of renal involvement was seen in 9.3% in children 
compared to 7.3% in adults.  
Children present as idiopathic thrombocytopenia (ITP) and 
haemolytic anaemia (AIHA) initially for few months to years and some 
of them gradually progress to have others features of SLE36. 
In this study there were 2 adults and 2 children with ITP and 2 children 
with AIHA who evolved into SLE. 
Perez et al found in 1985 6 out of 18 patients with ITP had ANA 
positivity and 4 out of 18 evolved into SLE. 
Dubois et al reported AIHA (2-6%) in childhood onset of SLE.  
5 out of 10  AIHA patients studied by Viedeback et al in 1962 
evolved into SLE. 
During cumulative disease there was involvement of internal 
organs like the kidney, heart, lung, brain, bonemarrow and vessels. 
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Clinical 
Manifestation 
Dubois 
(1971)
Malaviya
(1985)
Vaidya 
(1997)
Binoy 
(2003)
Arthritis 92% 66% 70. 9% 89. 3%
Dermatological 71. 5% 85% - 64% 
Malar rash - - 53. 18% 40% 
Discoid - - - 5. 3%
Photo 43% - 9. 55% 33% 
Oralulcer 9. 1% 64% - 64%
Alopecia 21% 82% - 60% 
Raynaud’s 18. 4% 32% 15. 5% 2. 7%
Renal 46. 1% 73% 35% 33. 3% 
Pulmonary 45% 17% 15. 5% 8% 
Cardiovascular 30. 5% 5% 11. 8% 5. 3%
Neuropsychiatric 25. 5% 15% 25. 5% 13. 3%
 
Certain features like fever, anaemia, lymphadenopathy, cutaneous 
lesions and transient metabolic parameters showed abnormalities during 
disease flare.  
In this study, the arthritis  was seen  in 52% of children and 58% in 
adults as compared to 89% in NK study. The deformable arthritis Jaccoud’s 
was seen in 12.5 % in children and 13.2% in adults in this study. The 
component of ligament laxity and periarticular capsular fibrosis is the cause of 
this deformity.  
Avascular necrosis was seen in 12.5% in children more than in 
adults (4.4%). In this present study one child had LAC positivity with 
avascular necrosis.  
A cross sectional study by Bergstein J. et al in 1974, of 35 
children with SLE  found evidence of AVN in 40%. This may probably 
due to steroid effects, APLS.  
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Dermatological manifestation was seen in 52% of children, 75% 
in adults and was comparable to NK of 64% and NI (Malaviya A.N. etal 
37) of 85%. 
SCLE Lesions 28% were seen in adults compared to 1% in 
Children This may be because of influence of sun light exposure and sex 
hormones triggering auto immune presses in skin. DLE lesions was seen 
5.8% in adults and 1% in children comparable to NK study.       
Alopecia was seen in 48%of children and 57% adults, which was 
lower than NK with 60% and NI with 82%. Oral ulcers was seen in 44% 
and 68% in children and adults respectively which was comparable to 
NK of 64% and NI 64%.  
Dyschromia was seen in 22% in children and 65% in adults in the 
present study as compared to the previous studies, which quote about 20%. 
This may be due to a chronic nail bed micro circulatory disturbance.  
Kozolav L.K et al described various microcirculatory disorders in 
SLE  disease where in  chronic inflammation, hypoxia affected tissue 
nutrition which may be a factor. 
Hepatomegly, was seen in 55% in children 9% in adults . 
Lymphadenopathy was seen in 55% in children and 25% in adults. 
Reticuloendothelial system response is  exaggerated physiologically in 
children compared to  adults with SLE.  
Pericardial effusion was found to be 18.7% in children and 14.7% 
in adult and valvular abnormalities disease was seen in 9% children and 
5% in adults. 
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Migajo et al described 1997 in his study that pericardial effusion 
was seen in 12% and valvular abnormalities in 34%, and of Mitral valve 
was 17%.  
1 patient in this study had coronary heart disease. 
Homcy et al is 1982 described 6 Ischaemic heart disease patients 
among 16-29 years age group, in his SLE study. 
Doherty et al described 30 patients below 35 years with 
Ischaemic heart disease. This shows the magnitude of premature 
athoeroselerosis in SLE.  
4 adult cases had developed Pulmonary hypertension and one had 
shrinking lung syndrome, and two had interstitial lung disease in this 
present study.  
Dubois et al observed 2 symptomatic patients with PHT in his 
study group. 
Perez et al observed 4 patients with PHT among 43 SLE, over a 
period of 2 years. 
Simmonson et al showed 5 patients out of 36 SLE had PHT by 
using 2D ECHO. 
Severe pulmonary upper airway obstruction was seen in 1 patient 
in this present study who had severe laryngeal edema, immobile left 
vocoal cord, which was reversed with intralesional steroids. 
Anita Karim et al in 2002 described a patient with similar 
presentation but did not reverse with steroids but under went 
tracheostomy68. 
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One had shrinking lung syndrome (1.4%) in adults in this study. It 
is an uncommon pulmonary manifestation11. 
Acute lupus pneumonitis occurred in 9.3% in children compared 
to 5.8% in adults. Dubois et al reported pneumonitis up to 14% in his 
study. 
Two adults had ILD (2.9%) of 3 years disease duration. Eisenberg 
et al reported 18 patients with SLE and ILD with mean age 45.7 years 
and disease duration of 10.7 years. This showed that ILD occurs in late 
stage of the disease. In this study disease duration for the development 
of ILD was three years. 
In 2004 Cefti E et al noticed rarity of ILD in his study population 
who were followed up for 10 years65.   
Renal manifestation was seen in 65% in children and 44% in 
adults comparable to the NI of 73% and (NI) 33.3%. Only 6 children and 
11 adults were subjected to biopsy. This was because we took cases for 
biopsy if they showed persistent urinary findings. Hence the 
asymptomatic patients were not subjected to biopsy. 4 children and 5 
adults had nephrotic range of proteinuria.  
Among 6 children who underwent biopsy Class II-1, class III-1, 
class IV –2, Class V –2 and in adults class II- 1,class III-1, Class IV 
5,ClassV-4. Patients with renal involvement and also who had nephrotic 
range of proteinuria were taken for Doppler evaluation of carotids. 
Among Neuro psychiatric manifestations, two cases of adults had CVA, 
also complicated by hypertension. Two adults had LAC positivity. In this study 
the above two patients manifested with intractable seizures, intracranial tension 
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and their MRI showed hyper intense lesions on T2 weighted images one of the 
marker for CNS involvement. (Plate 4). 
Among CNS manifestation seizures noticed in 30% of children 
compared to adult. It was found to be increased in Tucker et al study of 
childhood SLE. 
Chorea which had been reported in 2-3% in previous study was 
not seen in this present study among children and adult. 2 adult patients 
had CVA without associated systemic hypertension. One child 
developed catastrophic APLS40. 
Among laboratory parameters, ANA positivity was seen in 97. 1% 
in children and 95. 6% in adults. Complements were seen to be 
decreased C3 in 18. 75% and 13. 2% of C4 in children, 3. 75% and 3. 
5% in adults respectively. LAC positivity was seen in 9.3% in children 
and 10.2% in adults. Among three cases of LAC +ve children,2 had 
renal lupus and one had catastrophic APL. Among 6 adults who were 
LAC+ve, 2 had PHT, 1 had renal lupus, 1 digital gangrene and 2 had NP 
lupus. 
ACL was seen in 16% in children and 13% in adult in this study.  
Two children who had manifested with ANA negative and ACL 
positivity, progressed to develop SLE. This has also been reported by 
Gatterne M et al in 2003 that out of 10 children who present with 
primary APLS, but two of them developed SLE62. 
MRI in this study was used to pick up lesions in CNS lupus.  
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Tom W.J. et al described different imaging modalities in CNS 
SLE can used to differentiate patients of active CNS SLE, from those 
cost by residual disease. (Symptoms being similar).   
Thus the clinical and laboratory profile showed the burden of the 
disease among the study population and various manifestation of 
vascular involvement. 
In the study group, none had a family history of atherosclerotic 
event. None were found to be diabetic. 
In this study the mean IMT in children was 0.421 and the mean 
IMT in adults was found to be 0.428. 
On analysis of the risk factors, it was found that smoking habit 
was seen in 3 adult males.  
Smoking did not correlate with IMT and plaque in adults and 
children. This factor was low in this part among women who formed the 
major group. 
Age was found to correlate with IMT in children and not in adults. 
Selzer et al in his study observed that atheroclerosis was found in 
older age groups. In this study adults were seen predominantly of 
younger age compared to Western study patients.  
Disease duration was found to correlate with IMT in adults 
p=0.04, but not in children. Petri et al in his study had seen that disease 
duration influenced the IMT and plaque. The longer the duration the 
more was the correlation. 
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Hypertension correlated in adults with plaque p=0.05 but not with 
IMT. Bruce et al in 2003 observed that hypertension and diabetic states 
in a study of 2500 SLE patients associate with higher risk of coronary 
artery disease.   
SLEDAI scoring did not correlate with IMT and Plaque in both 
children and adults.  
Mansi et al in his study observed that along with the traditional 
risk factors SLEDAI also influence the Doppler parameters. In this study 
SLEDAI was done at the point of evaluation of Doppler alone. Serial 
SLEDAI would be more helpful in the interpretation. 
Renal involvement did not influence the IMT and plaque in 
children and adults. Fallaschie et al in his study among childhood SLE 
had shown that renal involvement with nephrotic range of proteinuria 
contributed more to plaque formation. 
Steroid usage was found to correlate well with the development of 
plaque in children (p=0.001) and adults (p=0.04). Doria et al in his study 
showed that the steroid dose, (cumulative, duration) affected the plaque 
formation. 
On analysis of the lipid profiles from table 12,  
The total cholesterol was high in 5 children and in 16 adults.  
This showed that this component affected adults more than 
children.  
The LDL fraction was raised in 5 children and 10 adults.  
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Triglycerides was raised in 8 children and 28 adults. This may be 
due to steroid and also because of the disease per se. Similar findings 
were noticed in other studies also34,43,49,57. 
HDL is a component which is helpful to prevent the 
atherosclerosis and plaque formation.  
HDL was found in normal amounts in 22 of children and in 48 of 
the adults showing that in this part of the country in spite of the disease, 
majority of patients are having HDL in normal range. It is reduced in 12 
adults as compared to 3 children. 
In children IMT was well associated with triglycerides, but in the 
adults both total cholesterol and LDL cholesterol were significantly 
associated. Dyslipidemia has been noted in several studies43.  
The scatter diagram shows that significant values follow an 
upward trend between  IMT and the variables. 
Many Western studies showed SLE activity of 7-10 yrs to 
influence the plaque, but in this study, patients less than 3 yrs had 
developed plaques40,32. 
Swengsson et al in 2001, studied prevalence of traditional and 
nontraditional factors with or without CVS disease. In a cohort of 26 
patients, he found that IMT thickness (0.66±0.15) compared to controls 
(0.59±0.12). SLE patients had plaques  (17/26) compared to SLE 
controls (10/26). 
Sonia Jimenez et al in 2005 had studied preclinical 
atherosclerosis in three groups.  The groups were SLE, Primary APL and 
controls. He found that hypertension, hyper triglceridemias, persistent 
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disease activity, renal disease and chronicity of the disease influence the 
IMT more than APL and control groups. Only when the LAC positivity 
was taken into account the formation of plaque correlated. 
In this present study two patients with plaque among children 
,both had renal lupus. Among 3 adults who had plaques one had 
coronary heart disease, one had neuropsychiatric manifestation and 
another had pulmonary hypertension.  
Plaque was found to depend on LAC positivity in adults and 
children. This has been reported in various studies.  
Stenosis was found to be associated with presence of LAC 
(p=0.02) in children and lipid profiles (TCL, LDL,TGL) in adults 
(p=0.05). 
Spectral widening was associated with lipid components in adults 
only.  
The ratios of LDL/HDL and TCL/HDL are used as one of the 
markers in calculating high risk in atherosclersis44,48. In this study 
the above ratios were found to increase significantly the risk of 
developing intimomedial thickness in adults. 
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SUMMARY AND CONCLUSIONS 
This was a descriptive study of 32 children and 68 adults with 
SLE. The clinical profile had been discussed in both age groups. The 
highlighting feature was the association of lipid profile and the duplex 
Doppler.  
The female to male ratio in children was 7:1 and in adults 17:1. 
The mean age at diagnosis was 12. 6 yrs in children and 28 yrs in adults. 
The mean disease duration was 1. 2 yrs in children and 1. 18 in adults.  
The commonest initial manifestation in children were fever and 
arthritis whereas in adults cutaneous lesion and arthritis was observed. 
Dyschromia was found more in adults with SLE .  
ITP and AIHA were found to be commoner in children compared 
to adults. Pulmonary hypertension, Ischaemic heart disease, shrinking 
lung syndrome, were seen in lesser percentage in this study compared to 
other studies. Renal involvement was found to be more in children than 
adults. Hypertension with renal involvement was seen in 3 children and 
10 adults.  
MRI is the preferential modality for learning NP Lupus. 
The mean IMT in this study was found among children 0.421 and 
among adults was 0.428. 
Duplex Doppler had picked up stenosis and plaque in both 
children and adults. Plaques were associated with hypertension in 
children and adults. Older children had greater IMT. Disease duration 
correlated with the IMT in adults. Smoking did not influence the plaque 
or the IMT. SLEDAI did not correlate with the plaque and IMT. Renal 
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involvement did not significantly correlate in children and adults with 
plaque. Steroid usage influenced the development of plaque in children 
and in adults. 
IMT in adults was found significantly associated with TCL/HDL 
and LDL/HDL ratios. 
Dyslipidemia had affected all components of the lipids and also 
significantly altered the Total cholesterol /HDL and LDL/HDL. Lipid 
profile, complement level and presence of antiphospholipid antibody 
had contributed to some of the development of premature atherosclerosis 
in this study.  
Duplex Doppler can be used as early diagnostic tool for 
premature atherosclerosis. 
Intimomedial thickness can be used as surrogate marker in 
assessing atheroselerotic events in SLE patients. 
The IMT in adults with   age related atherosclerosis is 1. 2 mm 
and above but cutoff values in disease states like SLE has to be 
standardized to the geographical area, dietary habits and Body mass 
index.  
Notably the LDL/HDL ratio and the Total cholesterol /HDL ratio 
has to be in the lower range in order to prevent atherosclerosis. The 
disease activity has to be treated promptly, for prevention of premature 
atherosclerosis in SLE.  
Duplex Doppler study of the carotids must be done serially 
along with the evaluation of the disease activity during follow up of 
SLE patients.   
7 
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APPENDICES 
APPENDIX 1: American College of Rheumatology (ACR) 
Criteria for Diagnosis of SLE, 1997.  
THE 1982 REVISED ACR CRITERIA 
1. Malar rash Sparing the nasolabial folds 
2. Discoid rash Characterised by follicular plugging , atrophic 
scarring and keratotic scaling
3. Photo 
sensitivity 
Due to unusual reaction to sunlight 
4. Oral ulcers Usually painless 
5. Arthritis Non erosive involving ≥ 2 peripheral joints 
6. Serositis a. Pleuritis 
b. Pericarditis
7. Renal 
disorder 
a. Persistent proteinuria > 0.5 g/d or > 3+ 
b. Cellular casts – red cell, Hb, granular tubular 
etc. 
8. Neurologic 
disorder 
a. Seizures 
b. Psychosis
9. Haematologic 
disorder 
a. Hemolytic anemia 
b. Leukopenia < 4000 / mm3 } on more than 
c. Lymphopenia < 1500 / mm3 } 2 occasions 
d. Thrombocytopenia < 1 lakhs / mm3  
10. Immunologic 
disorder 
a. + ve LE cell 
b. Anti-ds DNA or 
c. Anti-Sm, or 
d. False + ve VDRL for atleast 6 months 
11. Antinuclear 
antibody 
Abnormal titre by immunofluorescence or an 
equivalent assay at any point in time in the 
absence of drugs known to induce ANAs.  
 
If four of these criteria are present at any time during the course 
of disease, a diagnosis of systematic lupus can be made with 98% 
specificity and 97% sensitivity. 
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APPENDIX 2: PROFORMA 
Name : 
Age : 
Sex : 
Address : 
Height :   Weight : 
History : Skin changes, Constitution,symptoms related to, 
Musculoskeletal, Respiratory, Cardiovascular, Neurological and Gastro 
Intestinal Symptoms.  
Past History : Gangrene, Pregnancyloss, DVT, CVA, CAD.  
Personal History : Smoking, Alchohol.  
Drug History : Steroids (Dose and Duration), Chloroquine, OCP, 
Statins, Supplements.  
Examination : General, Pulse, BP, Mucocutaneous lesions, Malar rash, 
Photo  sensitivity, Urticaria, Discoidlesions, Oral/Nasal Ulcers, 
Alopecia.  
Musculoskeletal : Arthralgia/Arthritis, Myalgia, Subcutaneous Nodules.  
Cardio Respiratory : Pericarditis/pericardial effusion, Pleurisy/pleural  
effusion.  
Genito Urinary : Proteinuria, Abnormal Sediment, Haematuria, WBCs,  
Casts.  
Haemolymphatic : Adenopathy, Hepatospleenomegaly.  
Neural System : CVA, Cranial nerve, Psychological and Peripheral  
nervous system and motor system assessment.  
16 
Ocular Lesions : Retinal changes, Uveitis, Dry Eye Syndrome.  
Vascular : Gangrene, Raynaud’s, Ischaemic Ulcers.  
Investigations : All investigation which includes haemogram. 
Biochemistry, relevant to SLE, along with serology – ANA, DSDNA, 
Complements, LAC, ACL.  
Duplex Doppler Study of Carotid A (Intimo-Medial Thickness, Spectral 
Wave form, Plaque, Stenosis).  
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APPENDEX 3:SLEDA1 
Weight Descriptor Weight Descriptor 
8 Seizure 4 Proteinuria  
(>0.5 g/day) 
8 Psychosis 4 Pyuria(>5 
WBC/hpf) 
8 Organic Brain 
Syndrome 
2 New rash 
8 Visual Disturbance 2 Alopecia 
8 Cranial N. Disorder 2 Mucosal Ulcers 
8 Lupus Headache 2 Pleurisy 
8 CVA 2 Pericarditis 
8 Vasculitis 2 Low Complement 
4 Arthritis 2 ↑DNA Binding 
4 Myositis 1 Fever(>38°C) 
4 Urinary Casts 1 ↓Platelets(< 
1Lakh/mm3) 
4 Hematuria(>5 
RBC/hpf) 
1 Leukopenia(<3000/ 
mm3) 
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APPENDEX 4 
System Lupus International Collaborating clinics / American 
College of Rheumatology Damage Index for Systemic Lupus 
Erythematosus* 
Item       Score 
Ocular (either eye, by clinical assessment)  1 
Any cataract, retinal changes    1 
Neuropsychiatric 
Caogntive impairment     1 
Seizures       1 
CVA        1 (2) 
Cranial or peripheral neuropathy   1 
Transverse myeilitis     1 
Renal 
Estimated or measured GFR, 50%   1 
Proteinuria for > 3.5 gm%    1 
ESRD       3 
Pulmonary 
PHT        1 
Pulmonary Fibrosis     1 
Shrinking lung syndrome    1  
Pleural fibrosis      1 
Pulmonary infarction     1 
Cardiovascular 
Angina or CBG      1 
Myocardial infarction     1(2) 
19 
Cardiomyopathy      1  
Valvular disease      1 
Pericarditis for 6 months    1  
Peripheral vascular disease    1  
Claudication for 6 months    1 
Significant tissue loss     1(2)  
Venous thrombosis     1  
Gastrointestinal 
Infarctionor resection of bowel below duodenum  1(2) 
Mesentric insufficiency     1 
Chronic peritonitis     1 
Stricture or upper GI tract surgery   1 
Musculoskeletal 
Muscle atrophy      1  
D forming arthritis     1 
Osteoporosiswith fracture    1 
Avascular necrosis     1(2)  
Osteomyelitis      1  
Skin  
Scarring chronic alopecia    1  
Extensive scarring     1 
Skin ulceration      1 
Premature gonadal failure    1 
Diabetes       1 
Malignancy       1(2) 
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APPENDIX :5 
 
Classification of LDL, Total, HDL Cholesterol(mg/dl) and serum 
Triglycerides (mg/ dl) 
LDL Cholesterol 
< 100 optimal 
Near optimal 
Borderline high 
High 
Very high 
Total Cholesterol  
<200 Normal 
200-239 Border line high  
>240 High 
HDL Cholesterol 
<40 Low 
>60 High 
Serum Triglycerides 
<150 Normal 
150-199 Border line high 
200-499 High  
>500 Very high 
200-239 
 ACUTE LE LESION  
 
 
 
 SCLE  
 DISCOID LE 
 NON SPECIFIC LE LESION 
 
 
FOOT DROP 
 
LUPUS NE PHRITIS 
 
MRI BRAIN 
 
DUPLEX DOPPLER 
 
CAROTID DOPPLER 
1 
MASTER CHART 
 
 
Name Age Sex Duration Rash Photo Oral u. 
Ac.Se
d 
24 
Pro Anemia Ln. Hs. Sero. Fits Arth. Hb. Tc. Dc. Pt. Lac. Acl. Ana. 
Ds.  
Dna 
C3- 
c4 Cxr Tcl. Hdl. Ldl. Tgl. 
Pla- 
que 
Ste- 
nosis Imt 
Sp. 
wid 
Steroid_ 
dosage 
Smo- 
king Renal Sledai Bp. 
SUM 17 1 12 1 1 1 0 .8 1 1 1 0 0 1 9.6 18600 51,47,2 1.8 0 0 1 0 0 1 145 40 87 90 0 0 0.47 0 20 0 0 18 0 
DHA 16 1 18 1 1 1 1 .7 1 1 0 0 0 1 14.4 5400 58,39,3 1 0 0 1 1 0 1 147 45 88 68 0 0 0.46 0 15 0 0 7 0 
SARA 14 1 1 1 1 1 0 1.8 1 1 1 1 1 1 10.2 7200 64,32,4 1.4 1 1 1 1 1 0 136 44 88 124 1 1 0.34 1 30 0 0 22 0 
PREM 11 1 6 0 0 1 0 1.6 1 1 1 0 0 1 6.8 4000 58,42 0.35 0 0 1 1 1 0 154 43 95 83 0 0 0.53 0 15 0 0 14 0 
KANA 10 1 12 1 1 1 1 2.0 1 0 1 0 1 0 8.8 10000 66,33,2 2 0 0 1 1 0 0 99 27 62 52 0 0 0.28 0 15 0 0 21 0 
BHAR 12 1 6 0 1 1 0 1.8 0 0 0 0 0 1 10.5 4600 62,38 1.6 0 0 1 0 0 0 174 33 120 108 0 0 0.31 0 30 0 0 27 1 
DWAR 15 0 12 1 1 1 1 1.6 1 0 1 1 0 1 8.2 5300 62,36,2 1.8 1 1 1 1 1 0 196 32 120 220 0 0 0.65 1 30 0 4 30 1 
PAD 14 1 24 1 1 1 1 1.5 0 0 0 0 0 1 10.4 7100 71,24,5 1.6 0 0 1 1 0 0 182 44 118 101 0 0 0.2 0 15 0 3 8 0 
DEEP 14 1 24 1 1 1 0 0.6 1 0 1 0 0 1 5.2 4600 54,38,18 0.75 0 0 1 1 1 0 221 44 145 158 0 0 0.55 1 20 0 0 20 0 
MAHES 12 1 12 1 1 0 0 0.2 0 1 0 0 0 1 10 7400 60,32,8 1.4 0 0 1 0 0 0 166 45 90 157 0 0 0.3 0 35 0 0 24 0 
UNBAR 18 1 24 1 1 1 1 1.7 1 0 1 0 0 1 9.8 4200 76,26,2 2.1 0 0 1 0 0 0 160 22 80 290 0 0 0.62 1 25 0 5 35 0 
NAGA 18 1 36 1 1 1 1 1.5 1 1 1 1 0 1 7.2 6200 60,37,3 1.8 1 0 1 1 1 0 188 32 114 210 1 1 0.52 1 40 0 5 30 1 
PURU 18 0 24 1 1 1 1 1.2 1 0 0 1 0 1 7.6 5200 60,26,14 1.2 0 0 1 1 1 0 201 54 101 234 0 0 0.48 1 10 0 4 11 1 
HEMA 12 1 24 1 1 1 0 1.2 0 0 1 0 0 1 9.2 9800 40,22,38 2.1 0 0 1 0 0 0 138 44 80 162 0 0 0.42 1 10 0 0 14 0 
RAJK 14 1 12 1 1 0 1 .15 1 0 1 0 0 1 8.1 4800 38,45,17 1.8 0 0 1 1 0 0 127 54 181 284 0 0 0.54 1 10 0 0 9 0 
GENO 18 1 24 1 1 1 0 0.1 1 0 1 0 0 1 6.8 12000 80,16,4 3.2 0 0 1 0 0 0 167 44 92 164 0 0 0.46 1 20 0 0 28 0 
SUDAR 14 1 24 1 1 1 0 0.5 1 0 0 0 0 1 8.6 11200 89,9,2 3.7 0 0 1 1 0 0 204 40 138 186 0 0 0.42 1 25 0 2 12 1 
DURGA 10 1 24 1 1 1 0 .3 0 0 1 0 0 1 9.5 9600 62,36,2 2.5 0 0 1 0 0 0 127 38 50 250 0 0 0.36 0 20 0 0 16 0 
VASIF 12 1 24 1 1 1 0 .1 1 0 0 0 0 1 9.2 8400 58,36,6 2.2 0 0 1 0 0 0 159 37 104 91 0 0 0.38 0 15 0 0 20 0 
RAMYA 18 1 24 1 1 1 0 .3 1 0 0 0 0 1 7.8 5000 48,46,6 3.1 0 0 1 0 0 0 144 42 76 96 0 0 0.47 0 25 0 0 25 1 
JAMUN 35 1 12 1 1 1 1 .2 1 1 1 0 O 0 8.2 4600 62,32,6 2.2 1 0 1 0 0 0 174 33 120 108 0 0 0.38 1 15 0 2 25 1 
RAMACH 40 0 6 0 0 1 0 1.5 1 0 1 1 0 1 12 3900 84,2,14 2.1 0 0 1 0 0 0 166 45 90 157 0 0 0.47 0 10 1 0 5 0 
ANITH 20 1 6 1 1 1 1 2 0 0 0 0 0 1 10.8 4600 52,38,10 1.2 0 0 1 0 0 0 236 39 149 238 0 1 0.56 1 5 0 0 4 0 
SRDE 24 1 24 1 1 1 1 2.5 1 0 0 1 0 1 9.8 7600 56,35,5 1.5 1 0 1 1 1 0 184 39 119 132 0 0 0.45 1 25 0 2 26 1 
JAYA 28 1 6 1 1 1 0 1.5 0 0 0 0 0 1 8.8 8200 62,36,2 1.8 0 0 1 0 0 0 218 49 151 92 0 1 0.48 1 10 0 0 4 0 
2 
Name Age Sex Duration Rash Photo Oral u. 
Ac.Se
d 
24 
Pro Anemia Ln. Hs. Sero. Fits Arth. Hb. Tc. Dc. Pt. Lac. Acl. Ana. 
Ds.  
Dna 
C3- 
c4 Cxr Tcl. Hdl. Ldl. Tgl. 
Pla- 
que 
Ste- 
nosis Imt 
Sp. 
wid 
Steroid_ 
dosage 
Smo- 
king Renal Sledai Bp. 
BAVA 40 1 36 1 1 1 0 2.2 1 0 1 1 0 1 9.1 6700 60,40 1.8 1 0 1 1 1 0 224 40 156 216 1 1 0.45 1 50 0 3 20 1 
RAHI 23 1 24 1 1 0 1 .3 1 0 0 0 0 1 6.8 5700 038,36,6 0.8 1 0 1 0 1 0 138 44 80 70 0 0 0.32 0 10 0 0 15 0 
VALAR 42 1 4 1 1 1 1 .2 0 0 0 0 0 1 11.6 8000 59,36,5 2.1 0 0 1 0 0 0 162 55 71 88 0 0 0.27 0 5 0 0 4 0 
ANJALAI 32 1 7 1 1 1 0 1.5 1 0 0 0 0 0 9.2 7800 60,38,2 2.1 0 0 1 1 1 0 189 40 112 128 0 0 0.42 0 10 0 0 6 0 
SUMATHI 28 1 6 1 1 1 1 2.5 1 0 0 0 0 1 8.4 5600 62,28,10 1.9 0 0 1 0 0 0 202 44 130 108 0 0 0.46 1 5 0 0 24 0 
SUMATHI 21 1 12 1 1 1 1 2 1 0 0 0 0 1 9.2 9800 44,47,9 1.12 0 0 1 1 0 0 200 49 132 96 0 1 0.47 1 15 0 0 23 0 
DANALAX 32 1 24 1 1 1 1 2 1 0 0 1 0 1 8.2 8800 84,12,4 4.6 0 0 1 0 1 0 150 37 104 91 0 0 0.43 0 30 0 0 35 1 
RAJALAX 32 1 6 1 1 1 0 .1 1 0 0 1 0 1 9.4 8100 56,36,8 1.6 0 0 1 0 0 0 100 36 52 60 0 0 0.45 1 10 0 0 7 0 
VIJAYA 34 1 24 1 1 1 1 2.5 1 0 0 1 0 1 7.6 8400 40,52,8 1.6 1 0 1 1 0 0 221 44 145 158 0 0 0.39 1 15 0 0 25 0 
YTHRA 21 1 24 1 1 1 1 .1 1 0 0 0 0 1 6.4 7600 46,38,16 1.4 1 0 1 0 0 0 256 38 175 244 0 1 0.48 1 10 0 0 26 0 
PARWIN 23 1 12 1 1 1 1 .2 1 0 0 0 0 1 7.6 7400 76,24 1.2 0 0 1 0 0 1 101 40 55 82 0 0 0.38 0 15 0 4 30 1 
PRASA 28 1 6 1 1 0 1 3.5 1 0 0 1 0 1 6.5 9800 60,38,2 1.1 0 0 1 0 1 1 182 44 118 101 0 0 0.41 1 25 0 5 15 0 
SAVITH 40 1 24 1 1 0 0 3.5 1 0 0 1 0 1 7.8 6000 55,43,2 1.4 0 0 1 1 0 0 185 39 77 344 0 1 0.36 1 20 0 0 10 0 
SELVE 20 0 6 0 0 0 0 1.2 1 0 1 0 0 1 6.2 9600 68,28,4 0.9 0 0 1 0 0 0 172 46 109 79 0 0 0.34 0 15 1 0 20 0 
SUVULAX 35 1 24 1 1 1 1 .2 1 0 0 1 0 1 8.2 7000 52,42,4 3.2 1 0 1 0 1 1 204 48 140 144 0 0 0.38 1 30 0 4 36 1 
USHA 38 1 6 1 1 1 1 .3 1 0 0 1 1 1 5.6 6800 77,33 1.8 0 0 1 0 0 0 202 43 137 112 0 0 0.53 1 10 0 3 20 1 
BALGAS 35 1 36 1 1 1 0 .5 1 0 0 1 0 1 7.4 7100 68,25,2 1.3 1 0 1 1 1 1 145 40 87 90 0 0 0.26 0 15 0 4 28 1 
KOKILA 21 1 18 1 1 0 0 .3 0 1 0 0 1 1 7.2 9800 68,28,4 1.1 1 1 1 0 0 0 198 50 115 168 1 1 0.52 1 10 0 0 4 1 
GEETHA 24 1 24 1 1 1 0 .6 1 0 0 1 0 1 7.7 8200 40,32,8 1.4 0 0 1 1 1 0 154 43 95 83 0 0 0.29 0 30 0 4 35 0 
DAISY 26 1 24 1 1 0 1 .2 1 1 1 0 0 0 10.7 7800 59,37,4 2.6 0 0 1 0 0 0 256 38 156 234 0 0 0.51 1 50 0 0 6 0 
VALAR 21 1 12 1 1 1 1 .6 0 0 0 0 0 1 10.7 7200 54,45,1 2.6 0 0 1 0 0 0 167 38 89 280 0 0 0.35 0 20 0 0 10 0 
SALSA 24 1 6 1 1 1 1 .7 1 0 0 0 0 1 7.2 3800 71,36,2 1.4 0 0 1 0 0 0 123 38 73 59 0 0 0.42 1 10 0 2 32 1 
SHAEELA 40 1 24 1 1 1 0 .1 0 1 1 1 1 1 11.4 4200 80,18,2 1.6 0 0 1 0 1 0 176 40 106 132 0 0 0.32 1 25 0 4 46 1 
SHANTHI 25 1 6 1 1 1 1 .8 1 0 0 1 0 1 5.6 4200 58,26,13 2.8 1 0 1 0 0 0 211 38 146 179 1 1 0.61 1 35 0 2 26 1 
SELVAM 26 0 6 1 1 1 1 1.1 1 1 0 0 0 1 12.8 8200 56,42,2 1.8 0 0 1 0 0 0 148 38 96 57 0 0 0.48 1 5 0 0 6 0 
 
 
